Testing a tool to adjust chemo doses and reduce treatment delays
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a computer algorithm called PAGODA that helps doctors adjust chemotherapy doses for people with gastrointestinal cancers. The goal is to prevent unplanned treatment delays while keeping the treatment effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed cancer in your digestive system, such as cancer of the esophagus, stomach, colon, or rectum.
- You must be about to start or have just started a type of chemotherapy called FOLFOX, and your doctor plans for you to have at least 4 cycles (each cycle is 14 days).
- You must be 18 years or older and able to care for yourself (ECOG score 0–2).
- Your blood counts and kidney and liver functions must be within safe limits as checked by blood tests.
- You cannot have had chemotherapy for your GI cancer before (except for the first cycle of FOLFOX).
- You must not have had a severe allergic reaction to any of the chemotherapy drugs used in FOLFOX.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adjusting the dose of chemotherapy drugs (5-FU or capecitabine plus oxaliplatin) based on a liver enzyme test can improve safety and effectiveness for people with gastrointestinal cancer who are starting this type of chemo for the first time.
This Phase 1 trial tests how well a tailored (response-adapted) chemotherapy plan works before surgery for stomach or gastroesophageal junction cancer. It aims to improve treatment planning while checking early safety.
This trial tests a modified version of a common chemotherapy combination (capecitabine and oxaliplatin) for people with gastrointestinal cancers who are not expected to be cured. It aims to see if a simpler treatment schedule can be just as effective while reducing side effects.
This study tests whether doctors can safely find the best dose of 5-FU, a chemotherapy medicine, for people with advanced gastrointestinal cancers. The goal is to reduce side effects while still treating the cancer effectively.
This trial tests a new drug called ASP2138 combined with chemotherapy and pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. It may help if your tumor has certain markers (CLDN18.2 and PD-L1) and you haven't had prior chemotherapy for advanced disease.
This Phase 1 trial tests PIPAC, a way to deliver anti-cancer medicine directly into the abdomen using a minimally invasive procedure. It is for people with peritoneal spread from certain cancers to see whether this approach is safe and potentially helpful.
Hear when a new Colon Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.